Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum DAD-13
- Development stage
- Unknown
- Lead developer
- Universitas Gadjah Mada
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactiplantibacillus plantarum DAD-13** is a specific probiotic strain of Lactiplantibacillus plantarum, originally isolated from "dadih", a traditional Indonesian fermented buffalo milk product[4]. This strain has been shown to survive passage through the gastrointestinal tract, adhere to intestinal mucosa, and exert beneficial physiological effects—such as modulating intestinal inflammation, enhancing production of short-chain fatty acids (specifically propionate and butyrate), and regulating immune responses by increasing anti-inflammatory cytokines (IL-10) and decreasing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β)[1][2][4]. It also produces bacteriocins with inhibitory activity against enteric pathogens. The mechanism is considered immune-modulatory and microbiome-modifying, providing potential benefits in inflammatory bowel disease (IBD)[1][2] and has been studied in sepsis for reducing inflammation[3]. Its genome carries genes supporting acid and bile tolerance, mucosal adherence, pathogen exclusion (competition), and bacteriocin (antimicrobial peptide) production[4].
- Brand names
- Vipilac
- Other names
- Lactobacillus plantarum DAD-13L. plantarum DAD-13FNCC 0461FNCC0461FNCC-0461
Beyond the preview
Go deeper on lactiplantibacillus plantarum DAD-13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum DAD-13.